Natural Capsules valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
Price multiples — at each FY-end close
0.64×——
0.74×——
Enterprise multiples
1.41×——
−354.21×——
−14.92×——
Yield
−17.5%——
−0.4%——
Reference — adjusted share basis
₹136.44——
−₹23.90−₹16.44₹0.59
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NATCAPSUQ₹136.44

Natural Capsules Limited

· Pharma & Health
₹ CrorePeersNECLIFEAAREYDRUGSBALPHARMAALPAKREBSBIOMEDICAMEQMEDICOVINEETLABMcap ₹142 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/B——0.64
P/Sales——0.74
Enterprise Multiples
EV/Sales——1.41
EV/EBITDA——-354.21
EV/EBIT——-14.92
Yield
Earnings Yield %——-17.52
FCF Yield %——-0.43
Reference — adjusted share basis
Price (FY-end close, adj.)——136.44
EPS (adj.)0.59-16.44-23.90
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.